[1]Tiemsani C, Huillard O, Arrondeau J, et al. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors : consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug MetabToxicol 2015 ; 11 : 785-94.
[2]Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients : A meta-analysis. Cancer Treat Rev 2013 ; 39 : 199-206.
[3]Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2013 ; 77 : 929-38.
[4]Klümpen H.J., Samer C.F., Mathijssen R.H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37:251-260.
[5]Yu K., Geng X., Chen M. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 2014;42:744-750.
[6]Xu C., Xue Z., Bing N. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23:2470-2471.
[7]Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGT1A9 genetic polymorphism in patients with solid tumors: A preliminary study. PLoS One 2012 ; 7 : e42875.
[8]Terada T., Noda S., Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125-134.
[9]Teo YL, Ho, HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review. Expert Opin Drug Metab Toxicol 2015 ; 11 : 231-42.
[10]Li X., Kamanacka T.M., Cameron D. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib : implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009;22:1736-1742.
[11]Chan E.C., New L.S., Chua T.B. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos. 2012;40:1414-1422.
[12]Hardy K.D., Wahlin M.D., Papageorgiou I. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependant hepatotoxicity : induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metab Dispos. 2014;42:162-171.
[13]Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 2013 ; 14 : 541-54.
[14]Spraggs C.F., Budde L.R., Briley L.P. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29:667-673.
[15]Krishnamoorthy S.K., Relias N., Sebastian S. Management of regorafenib-related toxicities. A review. Ther Adv Gastroenterol. 2015;8:285-297.
[16]Goodman V., Wang Q., Pandite L. Incidence and management of hepatic toxicity in pazopanib-treated patients. Ann Oncol. 2011;21:viii282. Suppl. 8
[17]Reuben A. Hy's law. Hepatology. 2004;39:574-578.
[18]Shah R.R., Roberts S.A., Shah D.R. A fresh perspective on comparing the FDA and the CHMP/EMA: Approval of antineoplastic tyrosine kinase inhibitors. Br J Clin Pharmacol. 2013;76:396-411.
[19]Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012 ; 7 : e7563.
[20]Inhibiteurs de la tyrosine kinase BCR-ABL : Glivec®, Sprycel®, Tasigna®, Bosulif®, Iclusig® – le dépistage du virus de l’hépatite B (VHB) doit être réalisé avant l’initiation du traitement, en raison du risque de réactivation de l’hépatite B. Lettre aux professionnels de santé. Information transmise sous l’autorité de l’ANSM. Avril 2016.
[21]Food and Drug Administration. Product reviews and labels. http :/www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 12 Jan 2013.
[22]Seki N., Uematsu K., Shibakuki R. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol. 2006;24:3213-3214. author reply 14-5
[23]Gastrointestinal stromal tumors : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl. 3):iii21-6.
[24]Kijima T., Shimizu T., Nonen S. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol. 2011;29:e588-e590.
[25]Ferrero D., Pogliani E.M., Rege-Cambrin G. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91:ECR27.